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The Issue: Getting an Answer
Sooner and Cheaper
Shortening trial time means reaching a
decision earlier as to whether a treatment
is effective—and saving money in the
process. With old, invasive, inefficient tests
of cure like those we have now for several
neglected tropical diseases, follow-up (and
total trial) times remain inefficiently and
uneconomically long. While the need to
licence new drugs is urgent for many of the
neglected tropical diseases, it frequently
takes 8–10 years from Phase 1 to licensure,
and sometimes even longer. Consider
visceral leishmaniasis: it has taken nearly
20 years and at least three different
organisations for paromomycin to find its
way to registration in India, and even
longer to take a final decision to terminate
the development of sitamaquine.
The need for efficiency is particularly
acute in drug development, and specifical-
ly in Phase 2 clinical trials, when one will
select the drug dose/schedule to be tested
at a larger scale in the Phase 3 (pivotal)
trials. Here, one wants to find out what
works and what doesn’t as quickly and
economically as possible. Transposing
results from non-clinical studies (in vitro
and in vivo experiments) in terms of
pharmacokinetic/dynamic correlation is
not easy, so one is often left with a variety
of potential doses and regimens to choose
from.
What Would Alternative Study
Designs Add?
Adaptive trials designs are increasingly
used by pharmaceutical companies to
improve efficiencies in the R&D process
[1]. This approach allows the possibility to
redesign the trial (sample size, number of
arms, etc.) based on the information
acquired through interim analyses. Se-
quential and group sequential [1] trials are
a special case of adaptive trials whereby
several interim analyses are done in order
to complete the trial earlier (interrupt
enrolment) based on the accumulated
information.
However, these methods work best for
diseases for which treatment response
becomes obvious shortly after treatment
rather than having to wait for 6 months
(visceral leishmaniasis), 18 months (oncho-
cerciasis [river blindness]; human African
trypanosomiasis [HAT; sleeping sickness]),
or a yet-to-be-defined period for chronic
Chagas disease. Tuberculosis is in the same
league (18 months from treatment start for
the initial assessment and another 12
months for final cure), while with ‘‘only’’
28–63 days of follow-up, malaria is com-
paratively much better in this sense. The
reason for such long follow-up times is that
patients who initially respond favourably
mayrelapselater,and suchcasescannotyet
be predicted by the current tests of cure.
There are several ways to specify early
termination procedures (for futility), allow
repeated analyses to be performed on
accumulated data, maintain pre-specified
a andb error,orstopthe trialassoonasthe
information is sufficient to reach a conclu-
sion [2]. These methods can be grouped as:
(i) sequential methods (sequential probabil-
ity ratio test and triangular test [2,3]) and
(ii) group sequential designs (Peto [4],
Pocock [5], and O’Brien-Fleming [6]
methods; a [7,8] and b [9] spending
function; etc.). This is a domain of ongoing
statistical research with existing methods
being improved and new ones developed.
Example: Triangular Test for
Visceral Leishmaniasis
We used a triangular design to study
different doses and durations of combina-
tion treatments for visceral leishmaniasis
in India [10]. Experimental studies had
been inconclusive [11] while toxicology
studies had shown the combinations to be
safe (preclinical toxicology studies on
several drug combinations have been
done, with no major safety concerns
identified [Drugs for Neglected Diseases
initiative (DNDi), data on file]).
The trial was designed as a randomized,
parallel-arm, non-comparative, open-label
study using the group-sequential triangular
test method to reach, with the minimum
number of subjects, an early decision as to
which of four regimens should be selected
for additional testing. With a type 1 error
a=5% and power 12b=95% assump-
tions, considering a failure rate ,10% as
adequate efficacy (the minimum detect-
able failure rate at the b=5% level) and a
failure rate $25% as insufficient efficacy,
the boundaries of the test were calculated
for H0 (p=p0) and Ha (p,pa) with
p0=0.25 and pa=0.10. Based on simu-
lations, we expected the sample path to
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sample size of 40 patients and the H0 non-
rejection line with an average sample size
between 20 and 25 patients. When, after
enrolling 45–46 patients per arm, all
treatments appeared equally and highly
effective, an additional 45 consecutive
patients were enrolled and non-randomly
assigned to a fifth regimen (Figure 1).
All 181 subjects in Groups A–D com-
pleted assigned the treatment, and on day
16, 100% showed parasite-free splenic
aspirate smears and fulfilled the criteria
for apparent cure (Figure 2). Following the
successful completion of this study in
India, DNDi used this design again in a
Phase 2 trial of anti-leishmania drug
combinations in Africa (ClinicalTrials.gov
NCT01067443).
Using this approach did not result in
shortening trial time; the maximum cal-
culated number of patients was to be
enrolled as all treatment regimens proved
very effective. However, an economy was
achieved in the number of trial subjects
and the time to reach a conclusion.
Though the two methods cannot be
strictly compared, a classical single-stage
comparative trial design, with a type 1
error a=5% and a power 12b=95%
and the null hypothesis of 90% efficacy,
would require a sample size of 580 patients
per arm to reach the significance level for
a regimen with 95% efficacy. The two
approaches test different hypotheses, but,
especially for dose-finding purposes, the
triangular test offers clear advantages in
screening different treatment regimens.
Better Measures of Treatment
Outcomes Are Needed to Make
Adaptive Designs Worthier
The main indication for adaptive trial
designs such as the triangular design will
indeed be in the futility setting; weeding out
ineffective experimental doses in Phase 2
and thus reducing the numberof patients at
risk of being exposed to ineffective doses.
This will shorten time to decision and
moderate expenses. It will be interesting to
see how the triangular design performs in
situations like African leishmaniasis (see
above) where treatments tend to be com-
paratively less effective than in India, and
thus arms could be dropped earlier. The
triangular design however would probably
be less useful in diseases like HAT for
example,whereend-of-treatmentoutcomes
tend to be less informative.
However, until and unless reliable
markers of treatment effects are found,
clinical trials and drug development for
neglected tropical diseases will be ham-
pered. More investments are needed in
this area. An expensive marker can be
tolerated for drug development (contrary
to patient management, which needs
inexpensive, non-invasive tests) because
the net result will be a curtailment of time
and overall cost of development. However,
such markers are notoriously difficult and
expensive to discover and validate; atten-
tion must be called to this area for the
required long-term investments to be
made. Meanwhile, immediate solutions
are also needed.
Beyond Traditional Approaches
What can be done now and with limited
resources?
Action must be taken to increase
awareness of the problem among research
funding organizations and the research
community itself for novel solutions to be
found and tested. Consideration should be
Figure 1. Design of the triangular test for a Phase 2 study of anti-leishmania drug combinations.
doi:10.1371/journal.pntd.0001545.g001
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areas (such as non-transmissible diseases).
It is hoped that this paper will stimulate
interest and broaden the debate.
In leishmaniasis treatment trials, as for
other diseases, an initial (apparent) cure
can be followed by a relapse (or a re-
infection, to complicate matters further),
whereby the final cure rate will be lower
than the initial one. So, a fundamental
question is how predictive of final cure the
initial response is. The answer may vary
with the outcome, disease, treatment,
parasite, and patient population, and thus
location of trial. In the leishmaniasis
triangular trial cited here, we used Day
16 for the decision based on initial cure
and 9 months (instead of the customary 6
months) for final cure. As all the treatment
regimens tested were highly effective, Day
16 proved to be a reliable indicator of
success; the same would apply to the other
extreme case of very ineffective treatments
(in our study, it would have required about
half as many patients). The problem will
reside in treatments that are only partly
effective, which will suppress parasite
replication temporarily or kill the majority
but not all the parasites; initially, these will
be missed by insensitive diagnostics, only
Figure 2. Patient enrolment in a Phase 2 study of visceral leishmaniasis with triangular design.
doi:10.1371/journal.pntd.0001545.g002
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follow-up.
To some extent, available tools may be fit
for purpose. For example, with no cheaper
tools in sight, trial sites could be provided
with some state-of-the-art tools such as real-
time (RT) PCR, which could predict cures
or relapses based on the number of orga-
nisms at the end of treatment with reason-
able accuracy [12]. However even RT-
PCRneedstobevalidatedandstandardised
for the respectivediseases.Currently DNDi,
Me ´d e c i n sS a n sF r o n t i e `res (MSF), the World
Health Organization (WHO: Special Pro-
gramme for Tropical Diseases [TDR], Pan-
American Health Organization [PAHO]),
and various researchers are working togeth-
er towards validating the use of quantitative
RT-PCR as treatment outcome measure in
Chagas disease.
But there may be also other options
involving imaginative, cost-effective ways
of constructing the evidence base to design
trials differently. In this paper we focus
more on Phase 2-type trials, but the
concept should be extended to larger
pivotal trials and pragmatic trials as well.
Progress has been made with the design
of tuberculosis and malaria treatment
trials, which will specially benefit Phase
2. For tuberculosis, concern has been
raised over the use of early-response
methods such as (extended) early bacteri-
cidal activity [13] and serial sputum
colony counts (SSCC) [12,14] to predict
efficacy, over shortened duration of follow-
up (how informative are results at 6
months instead of 2 years [15]), and over
more general design issues [16] and use of
surrogate endpoints [17]. In malaria, too,
research has been done on identifying
both optimal duration of follow-up for
establishing final response [18] and also
early outcome measures (Day 3) which are
predictive of parasite susceptibility [19].
Some of the examples above show that
research question-driven collection and anal-
yses of databases from previous trials are both
useful and cost-effective as a means of de-
veloping newer, evidence-based approaches.
In Summary
N Shortening trial time and reducing
requirements for patients saves time
and money, and spares patients from
unnecessary exposure: there is there-
fore both an economic and an ethical
motive for rationalizing trial design.
N Economies can be found with alterna-
tive clinical trial designs, such as
adaptive trials (especially in the futility
setting), though these are only partly
suited for neglected tropical diseases,
which have inadequate measures of
treatment outcomes.
N Research is needed into generating
better tests of treatment outcomes for
neglected tropical diseases, but size-
able long-term investments are re-
quired.
N New, imaginative approaches should
be investigated that will generate an
evidence base for alternative trial
designs.
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